Science Explorer Back to mapMap
Discussion
Company · Durham · United States

G1 Therapeutics (United States)

g1therapeutics.comROR OpenAlex
Research works
81
▲ 22% vs 2018-21
Citations
1.8k
22.1 per fractional work
Top-10% rate
11.8%
all institutions 10.0%
Open access
47%
world 40%
International
31%
world 18%
G1 Therapeutics (United States)

Not ranked overall: G1 Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does G1 Therapeutics (United States) work in?

In 2022-now, 64% of research at G1 Therapeutics (United States) is in Health Sciences, 31% in Life Sciences. Its largest fields are Medicine (63%), Biochemistry, Genetics and Molecular Biology (24%), Immunology and Microbiology (6%). It does 2.3× the world's share of Health Sciences.

Health Sciences: 21 fractional works · 63.6% of its workMedicine: 21 fractional works · 63.2% of its workOncology: 8 fractional works · 23.0% of its workPulmonary and Respiratory Medicine: 5 fractional works · 13.7% of its workPathology and Forensic Medicine: 1 fractional works · 4.0% of its workSurgery: 1 fractional works · 3.7% of its workEpidemiology: 1 fractional works · 2.4% of its workGenetics: 1 fractional works · 2.4% of its workRheumatology: 1 fractional works · 2.0% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 1.8% of its workHematology: 0 fractional works · 1.4% of its workPsychiatry and Mental health: 0 fractional works · 1.0% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.8% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.8% of its workInfectious Diseases: 0 fractional works · 0.6% of its workPhysiology: 0 fractional works · 0.6% of its workPharmacology: 0 fractional works · 0.6% of its workNeurology: 0 fractional works · 0.5% of its workOtorhinolaryngology: 0 fractional works · 0.4% of its workRehabilitation: 0 fractional works · 0.4% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.4% of its workHepatology: 0 fractional works · 0.4% of its workNephrology: 0 fractional works · 0.3% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.6% of its workHealth Professions: 0 fractional works · 0.4% of its workPhysical Therapy, Sports Therapy and Rehabilitation: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workLife Sciences: 10 fractional works · 30.7% of its workBiochemistry, Genetics and Molecular Biology: 8 fractional works · 24.0% of its workMolecular Biology: 5 fractional works · 14.9% of its workCancer Research: 1 fractional works · 4.0% of its workCell Biology: 1 fractional works · 1.7% of its workGenetics: 0 fractional works · 1.4% of its workBiophysics: 0 fractional works · 0.7% of its workBiotechnology: 0 fractional works · 0.5% of its workPhysiology: 0 fractional works · 0.5% of its workBiochemistry: 0 fractional works · 0.2% of its workImmunology and Microbiology: 2 fractional works · 5.6% of its workImmunology: 2 fractional works · 4.9% of its workMicrobiology: 0 fractional works · 0.5% of its workVirology: 0 fractional works · 0.2% of its workNeuroscience: 0 fractional works · 0.6% of its workEndocrine and Autonomic Systems: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.2% of its workPharmacology: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 0 fractional works · 0.1% of its workPhysical Sciences: 2 fractional works · 5.1% of its workEnvironmental Science: 1 fractional works · 2.2% of its workEcology: 0 fractional works · 1.2% of its workWater Science and Technology: 0 fractional works · 1.0% of its workChemistry: 1 fractional works · 1.7% of its workOrganic Chemistry: 1 fractional works · 1.7% of its workEngineering: 0 fractional works · 0.4% of its workBiomedical Engineering: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMathematics: 0 fractional works · 0.3% of its workModeling and Simulation: 0 fractional works · 0.3% of its workComputer Science: 0 fractional works · 0.2% of its workComputational Theory and Mathematics: 0 fractional works · 0.2% of its workMaterials Science: 0 fractional works · 0.2% of its workMaterials Chemistry: 0 fractional works · 0.2% of its workSocial Sciences: 0 fractional works · 0.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.6% of its workEconomics and Econometrics: 0 fractional works · 0.6% of its workDecision Sciences: 0 fractional works · 0.0% of its workALL ITS WORKG1 Therapeutics(United States)33fractional works, 2022-now
Life Sciences31%Physical Sciences5%Health Sciences64%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine2163.2%
    2. Health Professions00.4%
    1. Biochemistry, Genetics and Molecular Biology824.0%
    2. Immunology and Microbiology25.6%
    3. Neuroscience00.6%
    4. Pharmacology, Toxicology and Pharmaceutics00.2%
    5. Agricultural and Biological Sciences00.1%
    1. Environmental Science12.2%
    2. Chemistry11.7%
    3. Engineering00.4%
    4. Mathematics00.3%
    5. Computer Science00.2%
    6. Materials Science00.2%
    1. Economics, Econometrics and Finance00.6%
    2. Decision Sciences00.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.03× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.51× its world share, 8 worksBiochemistry, Geneti…Immunology and Microbiology: 5.57× its world share, 2 worksImmunology and Micro…Neuroscience: 0.39× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 0.71× its world share, 0 worksPharmacology, Toxico…Chemistry: 1.07× its world share, 1 worksChemistryComputer Science: 0.03× its world share, 0 worksComputer ScienceEngineering: 0.03× its world share, 0 worksEngineeringEnvironmental Science: 0.45× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.06× its world share, 0 worksMaterials ScienceMathematics: 0.29× its world share, 0 worksMathematicsHealth Professions: 0.17× its world share, 0 worksHealth ProfessionsMedicine: 3.28× its world share, 21 worksMedicineDecision Sciences: 0.03× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 0.29× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.6×. Every wedge is a field page.

All 15 fields, with their numbers
  1. Immunology and Microbiology5.57×2 works
  2. Biochemistry, Genetics and Molecular Biology4.51×8 works
  3. Medicine3.28×21 works
  4. Chemistry1.07×1 works
  5. Pharmacology, Toxicology and Pharmaceutics0.71×0 works
  6. Environmental Science0.45×1 works
  7. Neuroscience0.39×0 works
  8. Mathematics0.29×0 works
  9. Economics, Econometrics and Finance0.29×0 works
  10. Health Professions0.17×0 works
  11. Materials Science0.06×0 works
  12. Agricultural and Biological Sciences0.03×0 works
  13. Computer Science0.03×0 works
  14. Engineering0.03×0 works
  15. Decision Sciences0.03×0 works

Who are the top researchers at G1 Therapeutics (United States)?

Ranked on the quality score, Jay C. Strum, John Bisi and Jessica A. Sorrentino lead among researchers whose main affiliation is G1 Therapeutics (United States).

  1. 1 Jay C. Strum United States · #95,230 worldwide 8.9k citations · 143 works
  2. 2 John Bisi United States · #131,862 worldwide 4.4k citations · 101 works
  3. 3 Jessica A. Sorrentino United States · #155,220 worldwide 8.3k citations · 152 works
  4. 4 Andrew Paul Beelen United States · #1,003,414 worldwide 1.2k citations · 163 works
  5. 5 Rajesh K. Malik United States · #2,306,297 worldwide 3.2k citations · 129 works
All ranked researchers at G1 Therapeutics (United States)

What are the most cited papers from G1 Therapeutics (United States)?

The most cited paper from G1 Therapeutics (United States) is "Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension" (Ronald J. Raymond, Alan L. Hinderliter, Park W. Willis et al., 2002), with 831 citations. Next come "CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation" (801) and "Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification" (370).

Most cited papers
#PaperReleasedCitations
1 Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension Ronald J. Raymond, Alan L. Hinderliter, Park W. Willis et al. · Journal of the American College of Cardiology Open access Apr 2002 831
2 CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation Jiehui Deng et al. · Cancer Discovery Open access 3 Nov 2017 801
3 Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification Patrick J. Roberts, Natalia Mitin, Patricia J. Keller et al. · Journal of Biological Chemistry Open access 10 Jul 2008 370
4 Production of Recombinant Adeno-associated Virus Vectors Using Suspension HEK293 Cells and Continuous Harvest of Vector From the Culture Media for GMP FIX and FLT1 Clinical Vector Joshua C. Grieger, Stephen Soltys, Richard Jude Samulski · Molecular Therapy Open access 6 Oct 2015 327
5 Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo Christopher C. Nixon et al. · Nature Open access 22 Jan 2020 323
All 60 most cited papers, with filters and sorting

Which keywords describe research at G1 Therapeutics (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Targeted Therapy, Prognostic Factors, Tumor Microenvironment, Metastatic Breast Cancer, Clinical Trials and Cancer.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 27 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 27 words, with their numbers
  1. Chemotherapy4▲ 18×10 topics
  2. Immunotherapy4▲ 15×8 topics
  3. Targeted Therapy3▲ 45×4 topics
  4. Prognostic Factors3▲ 19×6 topics
  5. Cancer3▲ 6.0×10 topics
  6. Clinical Trials3▲ 12×4 topics
  7. Metastatic Breast Cancer3▲ 133×2 topics
  8. Tumor Microenvironment3▲ 17×7 topics
  9. Metastasis2▲ 20×4 topics
  10. Breast Cancer2▲ 26×2 topics
  11. Biomarkers2▲ 9.0×2 topics
  12. CDK4/6 Inhibitors2▲ 209×1 topic
  13. Genomic Profiles2▲ 140×1 topic
  14. Palbociclib2▲ 209×1 topic
  15. Small-Cell Lung Cancer2▲ 140×1 topic
  16. Inflammation2▲ 2.7×17 topics
  17. Molecular Characterization2▲ 25×4 topics
  18. Immune Checkpoint Blockade1▲ 36×1 topic
  19. PD-1 and PD-L11▲ 36×1 topic
  20. Somatic Mutations1▲ 53×2 topics
  21. Quality of Life1▲ 2.5×8 topics
  22. Antimicrobial Agents1▲ 211×1 topic
  23. Cancer Risk1▲ 15×2 topics
  24. Febrile Neutropenia1▲ 211×1 topic
  25. Genetic Testing1▲ 28×2 topics
  26. Hereditary Syndromes1▲ 100×1 topic
  27. Microsatellite Instability1▲ 100×1 topic

Which research topics does G1 Therapeutics (United States) publish most on?

By volume in 2022-now: Lung Cancer Research Studies, Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers and Neutropenia and Cancer Infections.

Lung Cancer Research Studies: 2 fractional worksAdvanced Breast Cancer Therapies: 2 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksNeutropenia and Cancer Infections: 1 fractional worksGenetic factors in colorectal cancer: 1 fractional worksCancer Genomics and Diag…1Cancer Genomics and Diagnostics: 1 fractional worksCancer Treatment and Pharmacology: 1 fractional worksCAR-T cell therapy research: 0 fractional worksVascular Anomalies and Treatments: 0 fractional worksOtitis Media and Relapsing Polychondritis: 0 fractional works
OncologyPulmonary and Respiratory MedicinePathology and Forensic MedicineCancer Research2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lung Cancer Research Studies Oncology 2 works
  2. 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
  3. 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
  4. 4 Neutropenia and Cancer Infections Oncology 1 works
  5. 5 Genetic factors in colorectal cancer Pathology and Forensic Medicine 1 works
  6. 6 Cancer Genomics and Diagnostics Cancer Research 1 works
  7. 7 Cancer Treatment and Pharmacology Oncology 1 works
  8. 8 CAR-T cell therapy research Oncology 0 works
  9. 9 Vascular Anomalies and Treatments Genetics 0 works
  10. 10 Otitis Media and Relapsing Polychondritis Rheumatology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.1%not open52.9%

World: 40% of research is openly available.

with international co-authors31.0%domestic only69.0%

World: 18% is written across borders.

How has G1 Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 22% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is G1 Therapeutics (United States) as a percentage of every work published that year, 0.000098% in 2024.

still counting0.00010%0.00020%G1 Therapeutics (United States)0.000100% in 2025200020102020

Fractional works of G1 Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Durham

All research institutions in Durham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about G1 Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.